Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679776 | 0.86 | NFE2L2 (0.44) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL4679780 | 0.86 | NFE2L2 (0.44) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL28250254 | 0.84 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL13570118 | 0.84 | NFE2L2 (0.60) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL9714159 | 0.84 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL3891812 | 0.84 | CYP1A1 (0.54) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL7453390 | 0.84 | CYP1A1 (0.54) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL10723109 | 0.84 | NFE2L2 (0.56) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL17580725 | 0.84 | NFE2L2 (0.56) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL118591 | 0.83 | NFE2L2 (0.79) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160462-B1 | LEOLIGIN DERIVATIVES AS PROLIFERATION INHIBITORS OF SMOOTH MUSCLE CELLS | UNIV WIEN TECH (AT) | 2023-11-22 | — | — | EP | disclosed |
| EP-4265602-A2 | LEOLIGIN DERIVATIVES AS PROLIFERATION INHIBITORS OF SMOOTH MUSCLE CELLS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2023-10-25 | — | — | EP | disclosed |
| US-20170157301-A1 | LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | TECHNISCHE UNIVERSITÄET WIEN (AT) | 2017-06-08 | — | — | US | disclosed |
| EP-3160462-A1 | LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | Technische Universität Wien (AT) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015196228-A1 | LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157301-A1 | LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | CCNH, MYLK, CCAR2 | NFE2L2 1629/4885CYP1A1 4557/4885CYP1A2 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.